VEGF165, Human
VEGF165, Human

Serial dilutions of Anti-VEGF165 Antibody were added into VEGF165, Human, No Tag : Biotinylated Human VEGF R2, His Avi Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 0.30 μg/ml.

VEGF165, Human

Measured by a reporter gene assay using HEK293T-KDR-NFAT Cell line. The ED50 for this effect is < 10 ng/mL (QC Test).

VEGF165, Human

Immobilized VEGF165, Human, No Tag at 1 μg/ml(100 μI/well) on the plate. Dose response curve for Biotinylated Human VEGF R1, His Avi Tag with the EC50 of 42.7ng/ml determined by ELISA.

VEGF165, Human

Immobilized VEGF165, Human, No Tag at 1 μg/ml (100 μI/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 3.1ng/ml determined by ELISA.

VEGF165, Human

Immobilized VEGF165, Human, No Tag at 5 μg/ml (100 μI/well) on the plate. Dose response curve for Human VEGF R2, His Tag with the EC50 of 1.56 μg/ml determined by ELISA.

VEGF165, Human

The purity of VEGF165, Human is greater than 95% as determined by SEC-HPLC.

VEGF165, Human

VEGF165, Human on Bis-Tris PAGE under reduced condition and Non reduced (N) condition. The purity is greater than 95%.

VEGF165, Human

Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.
Z05954
¥67,155.00

Ask us a question
Product Introduction
Species Human
Protein Construction
VEGF165 (Ala27-Arg191)_x000D_
Accession # P15692-4
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 0.05EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 19.2 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 20-30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • VEGF165, Human
    • VEGF165, Human

    Serial dilutions of Anti-VEGF165 Antibody were added into VEGF165, Human, No Tag : Biotinylated Human VEGF R2, His Avi Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 0.30 μg/ml.

  • VEGF165, Human
    • VEGF165, Human

    Measured by a reporter gene assay using HEK293T-KDR-NFAT Cell line. The ED50 for this effect is < 10 ng/mL (QC Test).

  • VEGF165, Human
    • VEGF165, Human

    Immobilized VEGF165, Human, No Tag at 1 μg/ml(100 μI/well) on the plate. Dose response curve for Biotinylated Human VEGF R1, His Avi Tag with the EC50 of 42.7ng/ml determined by ELISA.

  • VEGF165, Human
    • VEGF165, Human

    Immobilized VEGF165, Human, No Tag at 1 μg/ml (100 μI/well) on the plate. Dose response curve for Anti-VEGF165 Antibody, hFc Tag with the EC50 of 3.1ng/ml determined by ELISA.

  • VEGF165, Human
    • VEGF165, Human

    Immobilized VEGF165, Human, No Tag at 5 μg/ml (100 μI/well) on the plate. Dose response curve for Human VEGF R2, His Tag with the EC50 of 1.56 μg/ml determined by ELISA.

  • VEGF165, Human
    • VEGF165, Human

    The purity of VEGF165, Human is greater than 95% as determined by SEC-HPLC.

  • VEGF165, Human
    • VEGF165, Human

    VEGF165, Human on Bis-Tris PAGE under reduced condition and Non reduced (N) condition. The purity is greater than 95%.


Background
Target Background Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.
Synonyms VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609;VEGF-165

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.